Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo

There are still unmet medical needs for the treatment of glioblastoma (GBM), the most frequent and aggressive brain tumor worldwide. EGFRvIII, overexpressed in approximately 30% of GBM, has been regarded as a potential therapeutic target. In this study, we demonstrated that CH12, an anti-EGFRvIII mo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Xu, Wen, Bi, Yanyu, Kong, Juan, Zhang, Jiqin, Wang, Biao, Li, Kesang, Tian, Mi, Pan, Xiaorong, Shi, Bizhi, Gu, Jianren, Jiang, Hua, Kong, Xianming, Li, Zonghai
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5029739/
https://ncbi.nlm.nih.gov/pubmed/27029073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8407
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados